Peel Hunt Reaffirms Hold Rating for Circassia Pharmaceuticals (CIR)

Peel Hunt restated their hold rating on shares of Circassia Pharmaceuticals (LON:CIR) in a report issued on Wednesday morning.

Shares of CIR stock opened at GBX 90.80 ($1.27) on Wednesday. Circassia Pharmaceuticals has a 52 week low of GBX 76.75 ($1.08) and a 52 week high of GBX 115.61 ($1.62).

TRADEMARK VIOLATION NOTICE: “Peel Hunt Reaffirms Hold Rating for Circassia Pharmaceuticals (CIR)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at

Circassia Pharmaceuticals Company Profile

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply